{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.7","upperLimit":"52.0","value":"36.60"},{"groupId":"OG001","lowerLimit":"27.6","upperLimit":"44.0","value":"36.75"},{"groupId":"OG002","lowerLimit":"38.2","upperLimit":"90.3","value":"52.55"},{"groupId":"OG003","lowerLimit":"43.7","upperLimit":"66.1","value":"51.65"},{"groupId":"OG004","lowerLimit":"13.9","upperLimit":"33.1","value":"23.90"},{"groupId":"OG005","lowerLimit":"30.3","upperLimit":"63.0","value":"44.35"},{"groupId":"OG006","lowerLimit":"21.2","upperLimit":"40.1","value":"33.40"},{"groupId":"OG007","lowerLimit":"42.5","upperLimit":"241.0","value":"68.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"15"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"16.1","upperLimit":"38.2","value":"24.95"},{"groupId":"OG006","lowerLimit":"25.7","upperLimit":"98.9","value":"42.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"24.6","upperLimit":"54.6","value":"39.20"},{"groupId":"OG004","lowerLimit":"19.8","upperLimit":"46.0","value":"37.00"},{"groupId":"OG005","lowerLimit":"30.1","upperLimit":"233.0","value":"59.50"},{"groupId":"OG006","lowerLimit":"19.6","upperLimit":"70.8","value":"39.40"},{"groupId":"OG007","lowerLimit":"50.0","upperLimit":"85.5","value":"67.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"title":"WEEK 4 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.8","upperLimit":"67.8","value":"36.50"},{"groupId":"OG001","lowerLimit":"14.3","upperLimit":"78.6","value":"43.00"},{"groupId":"OG002","lowerLimit":"23.3","upperLimit":"65.1","value":"37.30"},{"groupId":"OG003","lowerLimit":"33.3","upperLimit":"67.7","value":"47.50"},{"groupId":"OG004","lowerLimit":"24.0","upperLimit":"49.5","value":"42.00"},{"groupId":"OG005","lowerLimit":"29.6","upperLimit":"73.8","value":"50.75"},{"groupId":"OG006","lowerLimit":"20.2","upperLimit":"63.0","value":"33.90"},{"groupId":"OG007","lowerLimit":"44.5","upperLimit":"67.6","value":"63.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"title":"WEEK 7 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"32.2","upperLimit":"60.4","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"46.5","upperLimit":"82.0","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 7 DAY 8"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"34.9","upperLimit":"34.9","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 7 DAY 11"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"41.0","upperLimit":"53.6","value":"42.70"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"64.6","upperLimit":"64.6","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"31.6","upperLimit":"44.2","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"36.9","upperLimit":"36.9","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG007","lowerLimit":"61.1","upperLimit":"61.1","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"WEEK 10 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"40.7","upperLimit":"40.7","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 10 DAY 8"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG000","lowerLimit":"37.0","upperLimit":"37.0","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG001","lowerLimit":"29.6","upperLimit":"29.6","value":"NA"},{"groupId":"OG002","lowerLimit":"27.8","upperLimit":"41.6","value":"33.30"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"68.4","upperLimit":"72.8","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG005","lowerLimit":"37.6","upperLimit":"51.2","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"49.5","upperLimit":"49.5","value":"NA"},{"groupId":"OG007","lowerLimit":"52.9","upperLimit":"85.3","value":"54.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"title":"WEEK 13 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"48.0","upperLimit":"48.0","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 13 DAY 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG004","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG005","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG006","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG007","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 7 Day 8, Week 7 Day 11, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8","title":"C-EOI for Belantamab Mafodotin (Total Antibody), Treatment B","type":"SECONDARY","unitOfMeasure":"ug/mL"}